Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) generates a steady flow of news as a major participant in pharmaceutical distribution, medical products manufacturing and distribution, home-health services, and specialty healthcare support. This CAH news page aggregates company press releases and third-party coverage so readers can follow how Cardinal Health’s strategy, operations, and capital decisions evolve over time.
Recent news highlights include updates on financial performance and outlook, such as first-quarter fiscal 2026 results reported via Form 8-K and subsequent press releases, where Cardinal Health discussed revenue growth, segment profit trends, and revised non-GAAP earnings guidance. The company also issues announcements about upcoming earnings releases and webcasts, providing dates and times for quarterly and annual results discussions.
Cardinal Health’s news flow also covers strategic initiatives and acquisitions. For example, the company has reported on its plan and subsequent completion of the acquisition of Solaris Health, described as a leading urology management services organization that adds scale to The Specialty Alliance. Other updates discuss growth in Specialty revenues, expansion of MSO platforms, and the role of BioPharma Solutions and Sonexus™ Access and Patient Support in serving manufacturer partners and patients.
Operational and infrastructure developments are another key news theme. Cardinal Health has announced a new flagship Pharmaceutical and Specialty Solutions forward distribution center in Indianapolis, Indiana, a Consumer Health Logistics Center in Ohio, and new and planned at-Home Solutions distribution centers in Texas and California, all emphasizing automation and technology to support distribution and logistics.
Investors and observers can also find capital markets and governance updates in Cardinal Health’s news, including public offerings of notes to fund acquisitions, quarterly dividend declarations approved by the Board of Directors, and information related to annual shareholder meetings. Bookmark this page to review Cardinal Health (CAH) news across earnings, acquisitions, infrastructure investments, and governance developments in one place.
Cardinal Health (NYSE: CAH) has launched Velocare™, a new supply chain solution that enables rapid delivery of medical supplies for hospital-level care at home, in collaboration with Medically Home. This pilot program aims to enhance patient care by delivering essential products within one to two hours. Utilizing Cardinal Health's logistics expertise, the initiative targets high-acuity patients who previously required hospitalization. The market for at-home healthcare could reach $265 billion by 2025, according to McKinsey, indicating significant growth potential for this venture.
Cardinal Health (NYSE: CAH) has formed a strategic collaboration with Transaction Data Systems (TDS) to integrate the Outcomes platform into over 18,000 pharmacy locations. This partnership aims to enhance pharmacist workflows by connecting payers and pharmaceutical companies for improved medication adherence and patient care. The integration is expected to drive operational efficiency and generate additional revenue through clinical services. Both companies emphasize their commitment to enhancing health outcomes in the pharmacy setting.
On November 8, 2022, Cardinal Health (NYSE: CAH) announced a quarterly dividend of $0.4957 per share, reflecting its ongoing commitment to return value to shareholders. This dividend is payable on January 15, 2023, to shareholders of record by the close of business on January 3, 2023. Cardinal Health continues to strengthen its position as a key player in the healthcare sector, with its substantial operations spanning over 30 countries and a dedicated workforce of approximately 44,000 employees.
Cardinal Health reported Q1 FY23 revenues of $49.6 billion, up 13% year-over-year, with GAAP operating earnings of $137 million and diluted EPS of $0.40. Non-GAAP operating earnings fell 20% to $423 million, mainly due to a decline in the Medical segment, while non-GAAP diluted EPS decreased 7% to $1.20. The company reaffirmed its fiscal year 2023 non-GAAP EPS guidance of $5.05 to $5.40, although it adjusted Medical segment profit outlook to expect a flat to 20% decline.
Cardinal Health (NYSE: CAH) unveiled the third edition of Rheumatology Insights, revealing a significant rise in rheumatologists' familiarity with biosimilars, increasing from 53% in 2020 to 76% in 2022. Comfort in prescribing these medications also grew from 41% to 62%. The report indicates a heightened readiness for new biosimilars anticipated in 2023, particularly for adalimumab, a key product. Additionally, the report addresses health inequities in rheumatology, with 85% of rheumatologists acknowledging their existence and 58% noting worsened mental health in patients since COVID-19.
Cardinal Health (NYSE: CAH) will release its first-quarter financial results for fiscal year 2023 on November 4, before the NYSE opens. A webcast discussion will follow at 8:30 a.m. Eastern. The presentation will be available on Cardinal Health's Investor Relations page with slides and a replay accessible until November 3, 2023. Cardinal Health, a leading distributor of pharmaceuticals and medical products, operates in over 30 countries with approximately 46,500 employees.
PayrHealth has announced a collaboration with Cardinal Health (NYSE: CAH) to simplify payor contracting for specialty physician practices, focusing on rheumatology and ophthalmology. This partnership leverages Cardinal Health's Advanced Practice Analytics Technology and PayrHealth's expertise, aiming to enhance financial performance and operational efficiency. The initiative allows practices to concentrate more on patient care by managing the complexities of payor contracts. The new service will expand to additional therapeutic areas in the future.
Cardinal Health (NYSE: CAH) appointed Debbie Weitzman as the new CEO of its Pharmaceutical Segment, effective September 19, following the resignation of Victor Crawford. Weitzman, previously President of Pharmaceutical Distribution, will oversee both the Pharmaceutical and Specialty Distribution businesses, which will report directly to her. This leadership change aims to strengthen focus on specialty distribution and streamline operations. The restructuring includes the elimination of the President role in Pharmaceutical Distribution.
On September 6, 2022, Cardinal Health (NYSE: CAH) announced significant governance enhancements, including the appointment of four new independent directors, as part of its long-term strategy influenced by Elliott Investment Management. The newly formed Business Review Committee will assess the company's strategy and operations, chaired by CEO Jason Hollar. Following the upcoming Annual Meeting, the Board will include 54% women and 23% racially or ethnically diverse members. Cardinal Health plans an investor day in 2023 to present findings and strategic guidance.
Cardinal Health reported an 11% revenue increase to $47.1 billion for Q4 FY22, with GAAP operating earnings of $36 million impacted by a $303 million non-cash impairment charge. Non-GAAP operating earnings rose 41% to $450 million, resulting in a non-GAAP diluted EPS of $1.05. The company generated $3.1 billion in operating cash flow for FY22 and expects non-GAAP EPS guidance for FY23 between $5.05 and $5.40. Leadership changes were announced, with Jason Hollar becoming CEO, effective September 2022, as part of ongoing strategic improvements.